To mitigate this immune evasion, anti-PD-1/PDL-1 treatments have been clinically developed for many tumors, such as non-small-cell lung cancer (NSCLC) [21], melanoma, and renal cell cancer. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.